Reference
Mital S, et al. Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups. PharmacoEconomics : 22 Sep 2020. Available from: URL: https://doi.org/10.1007/s40273-020-00962-y
Rights and permissions
About this article
Cite this article
Early-stage cost-effectiveness analysis of novel drug for T1DM prevention. PharmacoEcon Outcomes News 863, 12 (2020). https://doi.org/10.1007/s40274-020-7166-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7166-x